Click here to read more
Click here to read more
Stevenage, UK, 21 June 2018 – KaNDy Therapeutics, a UK clinical-stage biotech company, today announces the appointment of Jo Craig as Head of Chemistry Manufacturing and Controls for both KaNDy Therapeutics and NeRRe Therapeutics, its sister company.
Jo Craig joins from GlaxoSmithKline where she was most recently VP of Technology & Strategy, Product Development & Supply. Both companies have clinical stage assets in Phase II, and Jo’s responsibility will be to ensure that the assets are ready for Phase III from a CMC perspective at the next development milestone.
Jo joined GSK in 1984 and initially worked on Imigran to treat patients with debilitating migraines. She proceeded to hold roles of increasing responsibility in CMC product development, including work on Tivicay and Triumeq from the GlaxoSmithKline HIV portfolio, which launched in 2014/2015. More recently, Jo led the new global Process Robustness group across R&D and Manufacturing and, in 2016, went on to assume the role of Head of New Product Introduction Quality.
Jo holds a BPharm (first class honours) from the School of Pharmacy, University College, London, and is a registered Pharmacist and a member and Board advisor for the Academy of Pharmaceutical Sciences, UK.
Mary Kerr CEO of KaNDy Therapeutics and NeRRe Therapeutics, said: “I am delighted that Jo has decided to join the KaNDy and NeRRe teams at this critical time. Jo’s input will be invaluable and ensure that NT-814, KaNDY Therapeutics breakthrough treatment for symptoms of the menopause and orvepitant, NeRRe’s lead NK-1 receptor antagonist in development for the treatment of chronic cough, will both be fully Phase III ready from a CMC perspective in the near future.”
For more information, please contact:
Mary Kerr, Managing Director of KaNDy Therapeutics
Tel: +44 1438 906960
Consilium Strategic Communications
Mary-Jane Elliott/ Lindsey Neville/ Carina Jurs
Tel: +44 (0) 20 3709 5700
KaNDy Therapeutics is a clinical-stage company focused on optimizing the potential of NT-814 in the treatment of common, chronic debilitating female sex-hormone related conditions. These conditions, such as post-menopausal VMS, are debilitating for women often over many years and associated with significant healthcare and economic costs.